Icagen, Inc. - Strategic SWOT Analysis Review

Icagen, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.

Highlights

Icagen, Inc. (Icagen) (formerly known as XRpro Sciences, Inc.) is a biopharmaceutical company wioch develops drug candidates to unmet medical need and commercial opportunity. The company discovers drug for clinical stage across multiple therapeutics and ion class channel classes. The company provides technologies including high throughput fluorescence, manual and automated electrophysiology, and radiotracer flux.It offers screening services to pharmaceutical sector, including the use of proprietary x-ray fluorescence technology which is marketed as XRpro. It delivers ion channel and transporter screening, assay development, cell line generation and custom assay services. The company has collaborations with Pfizer, Inc. It is headquartered at Durham in North Carolina, United States.

Icagen, Inc. Key Recent Developments

May 16, 2016: Icagen Issued U.S. Patent Covering Diagnostic and Discovery Applications of its Proprietary XRpro X-Ray Fluorescence Technology
Feb 22, 2016: Aptuit and Icagen Agree to Strategic Alliance
Jan 21, 2016: Icagen to Showcase Ion Channel and Transporter Drug Discovery and Development Expertise at SLAS 2016
Oct 01, 2015: Icagen Launches Industry's Most Comprehensive Research Platform and Services for Sodium Channel Drug Discovery
Sep 30, 2015: Icagen Consolidates Operations at RTP Facility

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Frequently Asked Questions